India pharma companies develop versions of Wegovy to get in on weight-loss windfall

Indian drugmakers are developing their versions of Novo Nordisk's weight-loss treatment, Wegovy, aiming to capitalize on the growing weight-loss market, expected to reach $100 billion a year by the end of the decade. Companies like Sun Pharma, Cipla, Dr Reddy's, and Lupin are working on Wegovy alternatives as Novo Nordisk struggles to meet global demand.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news